Pharmacoeconomics and therapeutic drug monitoring

Pharmacy World and Science

Volumn 19, Issue 4, 1997, Pages 178-181

  Bootman, J Lyle ^a   Harrison, Donald L ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Clin Invest Regulatory Office   (United States)

Author keywords

Cost benefit; Cost effective; Pharmacoeconomic evaluation; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE; DIGOXIN; GENTAMICIN;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; ECONOMIC EVALUATION; HEALTH SERVICE; HUMAN; MORBIDITY; PHARMACEUTICAL CARE; PHARMACOECONOMICS; REIMBURSEMENT;

DRUG MONITORING; DRUG THERAPY; HUMANS; PHARMACOLOGY;

EID: 0030765718     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008634318875     Document Type: Article

References (32)

1. Bootman JL, Townsend RJ, McGhan WF. Introduction to pharmacoeconomics. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics, 2nd ed. Cincinnati, Ohio: Harvey Whitney Books Company, 1996:4-19.
2. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
3. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
4. Harrison DL, Draugalis JR. Pharmacoeconomics: types of studies. In: Health Economics in the USA. IMS America, Plymouth Meeting, PA, 1996:209-21.
5. McGhan WF, Rowland CR, Bootman JL. Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical services. Am JHosp Pharm 1978;35:133-40.
6. Bootman JL, Wertheimer AI, Zaske D, Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979;68:267-79.
7. Townsend R. Post-marketing drug research and development. Ann Pharmacother 1987;21:134.
8. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics, 1st ed. Cincinnati, Ohio: Harvey Whitney Books Company, 1991:4-19.
9. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
10. Strand LM, Cipolle R, Morley PC. Drug-related problems: their structure and function. DICP 1990;24:1093-7.
11. Manasse HR Jr. Medication use in an imperfect world, I: drug misad venturing as an issue of public policy. Am J Hosp Pharm 1989;46:929-44.
12. Manasse HR Jr. Medication use in an imperfect world, II: drug misadventuring as an issue of public policy. Am J Hosp Pharm 1989;46:1141-52.
13. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-56.
14. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990;2:19-33.
15. Crawford SY, Myers CE ASHP national survey of hospital based pharmaceutical services. Am J Hosp Pharm 1993;50:1371-1404.
16. Murphy JE, Slack MK, Campbell S. National survey of hospital based pharmacokinetic services. Am J Health-Syst Pharm 1996;53(in press).
17. Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clinical Pharmacokin 1987;13:131-40.
18. Mackeigan L, Bootman JL. A review of cost-benefit and cost-effectiveness of clinical pharmacy services. J Pharmaceut Marketing and Management, 1899;2:63-84.
19. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside levels with therapeutic outcome in gram negative pneumonia. Am JMed 1984;77:657-62.
20. O Elenbaas RM, Payne VW, Bootman JL et al. Demand for blood level testing service in an ambulatory geriatric population. J Am Ger Soc 1989;3:109-23.
21. Crist KD, Nahta MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 1987;9:306-10.
22. Destache CJ, Meyer SM, Padomek MJ, Ortmeier BG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. Ann Pharmacother 1989;23:33-8.
23. Kimelblatt BJ, Bradbury K, Chodoff L, Aggour T, Mehl B. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm 1986;43:1205-9.
24. Smith M, Murphy JE, Job ML, Ward ES. Aminoglycoside monitoring: use of a pharmacokinetic service versus physician recommendations. Hosp Formul 1987;22:92-102.
25. Sveska KJ, Roffe BD, Solomon DK, Hoffman RP. Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service. Am J Hosp Pharm 1985;42:2472-7.
26. Burton ME, Ash CL, Hill DP, Handy T, Shepherd MD, Vasko MR. A controlled trial of the cost-benefit of a computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991;49:685-94.
27. Destache CJ, Meyer SM, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990a;12:419-26.
28. Destache CJ, Meyer SM, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990b;12:427-33.
29. Eisenberg JM, Koffer H, Glick HA, Counell ML, Loss LE et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107:900-9.
30. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck XR et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167: 1739.
31. Bnarson T, McGhan WF, Bootman JL, Larson LN, Gardner ME Kligman EW. Demand for blood level testing service in an ambulatory geriatric population. J Am Ger Soc 1989;3:109-23.
32. Wade WE, McCall CY. Educational effort and CQI program improves ordering of serum digoxin levels. Hosp Formul 1994;72:567-73.